α 放射性核素切伦科夫发光成像的潜力。
The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides.
机构信息
Department of Physics, Stanford University, Stanford, CA 94305-4060, USA.
出版信息
Phys Med Biol. 2012 Feb 7;57(3):771-83. doi: 10.1088/0031-9155/57/3/771. Epub 2012 Jan 18.
Targeted α-emitting drugs are promising for cancer therapy, but cannot be effectively imaged by conventional techniques. Cerenkov luminescence imaging (CLI) has previously been shown capable of imaging β(+)- and β(-)-emitting radionuclides in vivo and could have the potential to image α-emitters. Cerenkov light production from α-emitters is through Compton scattering and from farther down the decay chain. This causes the Cerenkov production to vary in time and depend on sample geometry, complicating the interpretation of CLI images. We used the simulation toolkit Geant4 to predict the Cerenkov light output from five α-emitting radionuclides that have therapeutic potential: (225)Ac, (230)U, (213)Bi, (212)Bi and (212)At. We found that (225)Ac, (213)Bi and (212)Bi produced an order of magnitude more Cerenkov light than (18)F. However, the light from (225)Ac is delayed from the initial decay, possibly decreasing the correlation of the drug and light source. This indicates that CLI will not be helpful in the development of some α-emitting drugs.
靶向 α 发射药物在癌症治疗方面具有广阔的前景，但传统技术无法对其进行有效成像。Cerenkov 发光成像（CLI）先前已被证明能够对体内的 β(+)-和 β(-)-发射放射性核素进行成像，并且有可能对 α 发射体进行成像。α 发射体的 Cerenkov 光产生是通过康普顿散射和衰变链的更远端。这导致 Cerenkov 产生随时间变化，并且取决于样品几何形状，从而使 CLI 图像的解释变得复杂。我们使用 Geant4 模拟工具包来预测具有治疗潜力的五种 α 发射放射性核素（225）Ac、（230）U、（213）Bi、（212）Bi 和（212）At 的 Cerenkov 光输出。我们发现（225）Ac、（213）Bi 和（212）Bi 产生的 Cerenkov 光比（18）F 多一个数量级。然而，（225）Ac 的光来自初始衰变的延迟，这可能会降低药物和光源之间的相关性。这表明 CLI 在某些 α 发射药物的开发中可能没有帮助。
Zotero 插件